Interim data from ENERGY 3 trial highlight INZ-701's potential to modify disease course in ENPP1 Deficiency, with sustained ...

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

New research presented at Digestive Disease Week reveals that kissing after gluten consumption poses minimal risk to celiac ...

Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS ...

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type ...

Research and development expenses were $25.8 million for the quarter ended March 31, 2025, compared to $11.7 million for the ...

Kennesaw State University senior Kaden Buford likes being hands-on with exercise science, immersing in a clinical environment ...

Patients with neovascular age-related macular degeneration (nAMD) experienced improvements in central macular thickness and ...

Recent advances in developing cellular therapies, a broad group of strategies that use cells to treat disease, have shown efficacy in some types of blood c | Cancer ...

Alzheimer’s disease stands as the most widespread form of dementia globally, increasingly burdening families, healthcare systems, and societies as populations age. Although current treatments, ...

Objective Growing evidence suggests that coeliac disease (CeD) is more common in patients with inflammatory bowel disease ...

Q1 2025 Earnings Call Transcript May 12, 2025 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is ...